Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters

Therapeutic Methods and Therapies TCIM
Database
Language
Publication year range
1.
Neurotox Res ; 39(4): 1103-1115, 2021 Aug.
Article in English | MEDLINE | ID: mdl-33689146

ABSTRACT

Although many studies have reported toxic effects of cadmium (Cd) and lead (Pb) in the central nervous system, few studies have investigated the combined toxicity of Cd and Pb. The mechanisms by which these combined heavy metals induce toxicity, as well as effective means to exert neuroprotection from these agents, remain poorly understood. To investigate the protective effects of alpha-lipoic acid (α-LA) on Cd- and/or Pb-induced cortical damage in rats, 48 Sprague-Dawley rats were exposed to drinking water containing 50 mg/L of Cd and/or 300 mg/L of Pb for 12 weeks, in the presence or absence of α-LA co-treatment (50 mg/kg) via gavage. We observed that exposure to Cd and/or Pb decreased the brain weight/body weight ratio and increased Cd and/or Pb contents as well as ultrastructural damage to the cerebral cortex. Cd and/or Pb also induced endoplasmic-reticulum (ER) stress and activated Fas (CD95/APO-1)/Fas ligand (FasL) and mitochondrial apoptotic pathways. Furthermore, co-treatment of Cd and Pb further exacerbated part of these phenotypes than treatment of Cd or Pb alone. However, simultaneous supplementation with α-LA attenuated Cd and/or Pb-induced neurotoxicity by increasing the brain weight/body weight ratio, reducing Cd and/or Pb contents, ameliorating both nuclear/mitochondrial damage and ER stress, and attenuating activation of Fas/FasL and mitochondrial apoptotic pathways. Collectively, our results indicate that the accumulation of Cd and/or Pb causes cortical damage and that α-LA exerts protection against Cd- and/or Pb-induced neurotoxicity. These findings highlight that α-LA may be exploited for the treatment and prevention of Cd- and/or Pb-induced neurotoxicity.


Subject(s)
Cadmium/toxicity , Cerebral Cortex/drug effects , Endoplasmic Reticulum Stress/drug effects , Fas Ligand Protein/antagonists & inhibitors , Lead/toxicity , Thioctic Acid/pharmacology , fas Receptor/antagonists & inhibitors , Animals , Antioxidants/pharmacology , Apoptosis/drug effects , Apoptosis/physiology , Cerebral Cortex/metabolism , Cerebral Cortex/ultrastructure , Endoplasmic Reticulum Stress/physiology , Fas Ligand Protein/metabolism , Female , Mitochondria/drug effects , Mitochondria/metabolism , Mitochondria/ultrastructure , Rats , Rats, Sprague-Dawley , fas Receptor/metabolism
2.
Discov Med ; 21(115): 213-9, 2016 03.
Article in English | MEDLINE | ID: mdl-27115172

ABSTRACT

Immunotherapy has revolutionized treatment of cancers and autoimmune diseases. Bucking the trend, however, is type 1 diabetes (T1D), although it is one of best understood autoimmune diseases and individuals at genetic risk are identifiable with high certainty. Here we review the major obstacles associated with pan-B-cell-depletion using rituximab (RTX) and discuss the notion that B cell-directed therapy may be most effective as a preventive measure. We suggest that it will be more productive to aim at identifying and targeting autoreactive B cells rather than making adjustments to pan-B cell depletion and that non-conventional alternative therapies such as antibody blockade of FasL to bolster IL-10-producing Breg cells, which work successfully in mice, should be considered.


Subject(s)
B-Lymphocytes/drug effects , Diabetes Mellitus, Type 1/therapy , Immunologic Factors/therapeutic use , Immunotherapy/methods , Rituximab/therapeutic use , Animals , Antigens, CD20/immunology , Antigens, CD20/metabolism , Autoimmunity/drug effects , B-Lymphocytes/immunology , B-Lymphocytes/metabolism , Clinical Trials as Topic , Drug Therapy, Combination , Fas Ligand Protein/antagonists & inhibitors , Fas Ligand Protein/metabolism , Humans , Immunologic Factors/adverse effects , Immunotherapy/adverse effects , Interleukin-10/metabolism , Islets of Langerhans/immunology , Islets of Langerhans Transplantation/immunology , Mice , Rituximab/adverse effects , Treatment Outcome
3.
Eur J Neurosci ; 29(1): 114-31, 2009 Jan.
Article in English | MEDLINE | ID: mdl-19120440

ABSTRACT

Activation of the Fas receptor has been recently linked to apoptotic cell death after spinal cord injury (SCI). Although it is generally considered that Fas activation mediates apoptosis predominantly through the extrinsic pathway, we hypothesized that intrinsic mitochondrial signaling could be involved in the underlying mechanism of Fas-induced apoptosis after SCI. In the present study, we utilized the Fejota clip compression model of SCI at T5-6 in C57BL/6 Fas-deficient (lpr) and wild-type mice. Complementary studies were conducted using an in vitro model of trauma or a Fas-activating antibody to induce apoptosis in primary neuronal-glial mixed spinal cord cultures. After in vivo SCI, lpr mice, in comparison with wild-type mice, exhibited reduced numbers of terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)-positive cells at the lesion, reduced expression of truncation of Bid (tBid), apoptosis-inducing factor, activated caspase-9 and activated caspase-3, and increased expression of the antiapoptotic proteins Bcl-2 and Bcl-xL. After in vitro neurotrauma or the induction of Fas signaling by the Jo2 activating antibody, lpr spinal cord cultures showed an increased proportion of cells retaining mitochondrial membrane integrity and a reduction of tBid expression, caspase-9 and caspase-3 activation, and TUNEL-positive cells as compared to wild-type spinal cord cultures. The neutralization of Fas ligand (FasL) protected against traumatically induced or Fas-mediated caspase-3 activation and the loss of mitochondrial membrane potential and tBid expression in wild-type spinal cord cultures. However, in lpr spinal cord cultures, FasL neutralization had no protective effects. In summary, these data provide direct evidence for the induction of intrinsic mitochondrial signaling pathways following Fas activation after SCI.


Subject(s)
Apoptosis/physiology , Mitochondria/metabolism , Nerve Degeneration/metabolism , Signal Transduction/physiology , Spinal Cord Injuries/metabolism , fas Receptor/metabolism , Animals , Apoptosis Regulatory Proteins/metabolism , Cells, Cultured , Coculture Techniques , Disease Models, Animal , Fas Ligand Protein/antagonists & inhibitors , Fas Ligand Protein/metabolism , Female , In Situ Nick-End Labeling , Membrane Potential, Mitochondrial/genetics , Mice , Mice, Inbred C57BL , Mice, Knockout , Nerve Degeneration/etiology , Nerve Degeneration/physiopathology , Spinal Cord Injuries/physiopathology
4.
Pancreatology ; 7(1): 28-36, 2007.
Article in English | MEDLINE | ID: mdl-17449963

ABSTRACT

BACKGROUND/AIMS: Chronic pancreatitis is characterized by acinar destruction and fibrosis. We previously reported that apoptosis is involved in acinar destruction in chronic pancreatitis in the WBN/Kob rat. This study aimed to elucidate the antiapoptotic effect of Saikokeishito (TJ-10). METHODS: Four-week-old male WBN/Kob rats were fed a special pellet diet (MB-3) with or without TJ-10 (80 mg/100 g body weight) for 20 weeks. Pancreas was histopathologically examined every 4 weeks, and the expression of apoptosis-related factors such as Fas and Fas ligand (FasL) mRNA and protein was analyzed with RT-PCR, in situ hybridization and immunohistochemistry. Apoptosis was detected with a TUNEL method. RESULTS: In untreated WBN/Kob rats, chronic pancreatitis developed at 12 weeks and progressed with marked acinar cell destruction at 16 weeks. The expression of Fas and FasL peaked at 12 and 20 weeks. An apoptotic index in acinar cells correlated to the expression of Fas and FasL mRNA. However, in the TJ-10-treated rats, the rate of pancreatic acinar cell destruction, the apoptotic index at 12-20 weeks, and the expression of Fas and FasL at 12 and 20 weeks decreased significantly compared to those in untreated rats. CONCLUSION: These results suggest that TJ-10 has a therapeutic effect on chronic pancreatitis by the suppression of acinar cell apoptosis via the Fas/FasL system.


Subject(s)
Apoptosis/drug effects , Drugs, Chinese Herbal/therapeutic use , Herbal Medicine , Pancreas/drug effects , Pancreatitis, Chronic/drug therapy , Animals , Drugs, Chinese Herbal/pharmacology , Fas Ligand Protein/antagonists & inhibitors , Fas Ligand Protein/genetics , Fas Ligand Protein/metabolism , Male , Pancreas/pathology , RNA, Messenger/analysis , RNA, Messenger/metabolism , Rats , Rats, Inbred Strains , fas Receptor/antagonists & inhibitors , fas Receptor/genetics , fas Receptor/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL